Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

Ruben A. Mesa, Xiaopan Yao, Larry D. Cripe, Chin Yang Li, Mark Litzow, Elisabeth Paietta, Jacob M. Rowe, Ayalew Tefferi, Martin S. Tallman

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Abstract

A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose prednisone taper. Ten subjects received 3 months, and 25 received 6 months of therapy. Myelosuppression was the main toxicity with 88% with ≥ grade 3 hematologic toxicity and 45%≥ grade 3 nonhematologic toxicity. There were responses in 10 subjects (23%) using the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19%) and/or decreased spleen size in 4 (10%). Serial bone marrow analysis showed no resolution of disease-related fibrosis or angiogenesis. With a median follow-up of 2.3 years, 23 subjects are alive. Lenalidomide and prednisone for myelofibrosis evaluated through a multicenteredcooperative group mechanism is only modestly active and myelosuppresive. This study was registered at http:// clinicaltrials.gov as NCT00227591.

Original languageEnglish (US)
Pages (from-to)4436-4438
Number of pages3
JournalBlood
Volume116
Issue number22
DOIs
StatePublished - Nov 25 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903'. Together they form a unique fingerprint.

Cite this